Cumulative burden of abnormal visceral adiposity index and its components on the risk of hyperuricemia

Nutr Metab Cardiovasc Dis. 2023 Feb;33(2):340-349. doi: 10.1016/j.numecd.2022.11.016. Epub 2022 Nov 17.

Abstract

Background and aims: The visceral adiposity index (VAI), a gender-specific surrogate maker of adipose tissue distribution and function, is associated with risk of hyperuricemia. However, the impact of time-burden of abnormal VAI and its components on the risk of hyperuricemia remains unknown.

Methods and results: We included 56,537 participants without hyperuricemia and underwent two health examinations during 2006-2008 from the Kailuan study. Abnormal VAI burdens were evaluated as follows: (1) cumulative number of abnormal VAI presented at each examination (0-2 times); (2) cumulative number of each abnormal VAI component presented at each examination (0-2 times per component); (3) cumulative number of total abnormal VAI components presented at each examination (0-8 times). During a median follow-up of 8.81 years, 10,762 participants were diagnosed with hyperuricemia. The risk of hyperuricemia showed a positive association with cumulative number of abnormal VAI, the adjusted hazard ratio (HR) with 95% confidence interval (CI) of 2 times compared to 0 times was 1.69 (1.58-1.81). All four components of abnormal VAI, when diagnosed repeatedly, were independently associated with an increased risk of hyperuricemia, adjusted HR (95% CI) from 1.15 (1.02-1.28) for low high-density lipoprotein to 1.68 (1.58-1.79) for elevated triglyceride. The risk of hyperuricemia also gradually as abnormal components was accumulated from 0 to 8 counts, reaching an adjusted HR (95% CI) of 3.72 (2.64-5.23). Furthermore, the effect of cumulative abnormal VAI was more pronounced in females than males (P-interaction < 0.0001).

Conclusions: Cumulative abnormal VAI burdens were positively associated with the risk of hyperuricemia, especially in females.

Keywords: Cumulative burden; Hyperuricemia; Risk factor; Visceral adiposity index.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiposity*
  • Body Mass Index
  • Female
  • Humans
  • Hyperuricemia* / diagnosis
  • Hyperuricemia* / epidemiology
  • Intra-Abdominal Fat
  • Lipoproteins, HDL
  • Male
  • Obesity, Abdominal / diagnosis
  • Obesity, Abdominal / epidemiology
  • Obesity, Abdominal / metabolism
  • Risk Factors

Substances

  • Lipoproteins, HDL